This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

In the wake of Robert F. Kennedy Jr.’s abrupt revamp of the CDC’s Advisory Committee on Immunization Practices, details from ...

A leading infectious disease expert and one of the nation’s foremost COVID-19 researchers has voiced deep concerns about the ...

Robert F. Kennedy Jr. dismissed all members of the CDC’s Advisory Committee on Immunization Practices, which recommends which ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

The promise of mRNA technology seemed boundless after the success of the coronavirus vaccines, but Robert F. Kennedy Jr. has ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18 ...